ASCO 2018 June 1 - 5th, 2018 | Chicago, IL

ASCO is supported by its affiliate organization, the Conquer Cancer Foundation, which funds ground-breaking research and programs that make a tangible difference in the lives of people with cancer. This annual meeting is one of the largest oncology conferences there is and will bring together more than 32,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field.

We hope to see you there and set up a meeting with one of our oncology scientific leaders to discuss how we can further streamline your clinical trial!

AACR-ASCO

George Clinical's Scientific Leadership in Attendance

Sean Hart

  • Global Head of Late Phase and USA Managing Director

Sean Hart is the Managing Director USA and Global Head of Late Phase Studies for George Clinical. Prior to joining George Clinical, Sean was the Executive Vice President and Managing Director of Vector Oncology overseeing the Global Pharma Services team including early phase and observational research. Sean is a recognized industry leader in Phase IV clinical trials, post-marketing surveillance programs, and patient registries. His experience spans all major therapeutic areas and all phases of research and development.

Glenn Kerkhof, MBA

  • Executive Chairman, George Clinical

Glenn Kerkhof is Executive Chairman of George Clinical. Glenn has over 22 years’ experience in the contract research or drug development industry and joined George Clinical from Chiltern where he was Chief Executive Officer. Prior to Chiltern, Glenn served as Vice President, Clinical Services for Charles River Laboratories and as Vice President, Clinical Europe for Inveresk Research. In addition, he is also non-executive director of Cell Care Australia Pty. Ltd. and Immunoglobal Pty. Ltd. He holds a Bachelor of Commerce from Deakin University (Australia) and a Masters of Business Administration from the University of Edinburgh (UK).

Dr. Ari VanderWalde is an internationally-recognized cancer researcher, Dr. VanderWalde holds a dual appointment with the University of Tennessee Health Science Center as Associate Vice Chancellor of Research and Assistant Professor, Hematology/Oncology.

Dr. VanderWalde previously served as United States Medical Lead and Clinical Research Medical Director with Amgen Inc., directing US global development of talimogene laherparepvec, a novel viral-based immunotherapeutic that has shown efficacy in late-stage clinical trials in melanoma. As an expert in melanoma, Dr. VanderWalde has collaborated with some of the nation’s thought leaders and participated on advisory boards with top experts in the field.

Event Location

McCormick Place
2301 S King Dr
Chicago, IL
USA

Attending this event?

Meet with George Clinical! Contact us to schedule a time now.

George Clinical

customerservice@georgeclinical.com

Profits from George Clinical support the work of The George Institute for Global Health.

Join our Mailing List

Add George Clinical to your network